Respiratory Disease

Blu Biotech collaborates with University of Michigan on breath biomarkers for sepsis and ARDS detection

ARDS and sepsis are life-threatening and can be difficult to detect early. Blu Biotech, University of Michigan, and the Weil Institute seek to change that with the development of biomarkers for both conditions.

November 16, 2022

Cue Health's COVID test available to Canadian consumers

Cue Health last year began a partnership with Air Canada to provide U.S.-based passengers with access to the molecular COVID-19 test for their travel needs. Cue also provides tests to organizations like Johns Hopkins Medicine, the Mayo Clinic, Google, the National Basketball Association, and Major League Baseball, among others.

March 17, 2022

Eurofins subsidiary launches at-home test for 'forever chemicals'

These compounds tend to break down very slowly in both the environment and in people's bodies and exposure to them can cause cancer, thyroid disease, immune suppression, and respiratory disease as well as decrease fertility, Eurofins said. Identifying the presence of these compounds through a blood test is new, according to the firm.

January 23, 2022

Thermo Fisher completes Mesa Biotech acquisition

Mesa Biotech is known for its Accula system, a point-of-care polymerase chain reaction (PCR)-based testing platform for infectious disease diagnosis. Besides COVID-19, Accula also tests for influenza, respiratory syncytial virus (RSV), and group A Streptococcus.

February 25, 2021

Clinical trial planned for COVID-19 rapid breath test

The investigational BreathTest-1000 mass spectrometer is being positioned as a noninvasive, self-administered test of breath samples for various COVID-19 strains. The developers envisage that relative to the gold standard for COVID-19 detection, polymerase chain reaction (PCR) tests, their product would be a lower-cost, more convenient option suitable for wide distribution.

October 20, 2020

Siemens wins clearance in Canada for SARS-CoV-2 test

The molecular diagnostic is designed to positively identify the virus in less than three hours, according to the vendor. The kit, which consists of a single-well dual target assay, was authorized for sale by Health Canada under the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19, Siemens said.

July 28, 2020

Most Popular

Genetic causes identified for three rare diseases

Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease

FDA reissues EUA for Janssen COVID-19 vaccine, includes warning about risks of myocarditis, pericarditis

National hepatitis C elimination program represents an historic opportunity, according to White House

Chicago man indicted for COVID-19 testing fraud

Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test

Universal COVID-19 testing advised for long-term care facilities

At the start of the COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention (CDC) recommended that only patients who exhibited symptoms consistent with COVID-19 (such as fever, cough, and other respiratory symptoms) should be tested for the disease. However, long-term care facilities have been a hot spot for SARS-CoV-2 infections, and mortality rates have remained high.

July 14, 2020

Week in Review: Getting to know COVID-19 | Biomarkers for preeclampsia, liver disease | Quest puts HPV/Pap cotesting to the test

Dear LabPulse Member,

July 9, 2020

Diagnostics wanted for emerging infections, tomorrow's pandemics

In a 2018 global IVD market report, Kalorama Information lead analyst Shara Rosen wrote that the dark side of globalism is the spread of unwanted conditions. There are many examples of previously unknown or rare pathogens that spread and became a major problem globally -- this can happen rapidly with people traveling by air throughout the world, Rosen noted.

June 18, 2020

More stool PCR testing likely needed in COVID-19 patients

COVID-19 is commonly seen as a respiratory disease and much of the focus for diagnosis and also discharge of patients from hospitals following recovery has understandably been on the status of respiratory specimens. But gastrointestinal symptoms are also part of the disease and deserve more attention to help "prevent further spread of this highly contagious pathogen," wrote Dr. Sravanthi Parasa, a gastroenterologist at Swedish Medical Center in Seattle, and colleagues.

June 11, 2020

What is the impact of aerosolized SARS-CoV-2 in hospitals?

According to the U.S. Centers for Disease Control and Prevention (CDC), the SARS-CoV-2 virus in humans is thought to mainly spread between people through inhalation of respiratory droplets laden with the virus, as well as by touching contaminated surfaces followed by touching susceptible areas of the body, like the mouth, nose, or eyes.

April 29, 2020

Veracyte licenses gene signature for idiopathic pulmonary fibrosis

Developed by Yale's Dr. Naftali Kaminski and colleagues, the test predicts rapid disease progression associated with IPF. Experience with the gene signature in a multicenter study was published by Kaminski et al in Lancet Respiratory Medicine (November 2017, Vol. 11, pp. 857-868). Some 200,000 patients in the U.S. and Europe are evaluated for IPF and other interstitial lung diseases every year and knowing the severity of the disease could help guide them to the right treatments, the company noted.

April 23, 2020

Page 1 of 3

Next Page